Related Experiment Video
Updated: Mar 21, 2026
07:34
Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS
Published on: March 14, 2013
13.6K
Pancreatic cancer screening using a multiplatform human serum metabolomics system
Arata Sakai1, Makoto Suzuki1, Takashi Kobayashi1
1Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan.
Biomarkers in Medicine
|May 13, 2016
Summary
A new multiplatform metabolomics system shows promise for early pancreatic cancer detection. This novel screening method achieved high sensitivity and specificity in distinguishing patients from healthy individuals.
Area of Science:
- Biochemistry
- Oncology
- Analytical Chemistry
Background:
- Pancreatic cancer diagnosis remains challenging, often relying on late-stage detection.
- Developing sensitive and specific early screening methods is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate a novel screening method for pancreatic cancer using advanced metabolomics techniques.
- To assess the diagnostic performance of a multiplatform metabolomics system in identifying pancreatic cancer.
Main Methods:
- Serum samples from pancreatic cancer patients and healthy controls were analyzed using gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry.
- A diagnostic model was developed and validated using a two-phase screening approach on training and validation sets.
Main Results:
- The diagnostic model demonstrated high sensitivity (100%) and specificity (80%) on the training set.
- On the validation set, the model achieved a sensitivity of 84.1% and specificity of 84.1% for pancreatic cancer detection.
Conclusions:
- A robust diagnostic model for pancreatic cancer was successfully developed.
- The multiplatform serum metabolomics system offers a promising approach for pancreatic cancer screening.
